<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The potential of the metal-binding protein, metallothionein, in assessing the progression of <z:mpath ids='MPATH_458'>normal</z:mpath> oesophagus through Barrett's to <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> was investigated </plain></SENT>
<SENT sid="1" pm="."><plain>Metallothionein was quantitatively determined in resected tissues from patients undergoing oesophagectomy for high grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>/<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and in biopsies from patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In 10 cancer patients, metallothionein concentrations in <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> were not significantly different from <z:mpath ids='MPATH_458'>normal</z:mpath> oesophagus, although six had elevated metallothionein concentrations in the <z:mpath ids='MPATH_605'>metaplastic tissue</z:mpath> bordering the <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In 17 out of 20 non-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients with Barrett's epithelium, metallothionein was significantly increased by 108% (P&lt;0.004) </plain></SENT>
<SENT sid="4" pm="."><plain>There was no association between the metallothionein levels in Barrett's epithelium and the presence of inflammatory cells, <z:mpath ids='MPATH_160'>metaplasia</z:mpath> or <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>Metallothionein is a marker of progression from <z:mpath ids='MPATH_458'>normal</z:mpath> to Barrett's epithelium but is not increased in oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>